Biolase Debt to Equity Ratio 2010-2024 | BIOL
Current and historical debt to equity ratio values for Biolase (BIOL) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Biolase debt/equity for the three months ending June 30, 2024 was 0.00.
Biolase Debt/Equity Ratio Historical Data |
Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
2024-06-30 |
$0.03B |
$-0.00B |
-15.41 |
2024-03-31 |
$0.03B |
$0.00B |
126.71 |
2023-12-31 |
$0.03B |
$0.00B |
16.95 |
2023-09-30 |
$0.03B |
$0.01B |
5.59 |
2023-06-30 |
$0.03B |
$0.01B |
4.40 |
2023-03-31 |
$0.03B |
$0.01B |
4.14 |
2022-12-31 |
$0.03B |
$0.01B |
6.81 |
2022-09-30 |
$0.03B |
$0.01B |
2.09 |
2022-06-30 |
$0.03B |
$0.02B |
1.35 |
2022-03-31 |
$0.03B |
$0.02B |
1.44 |
2021-12-31 |
$0.03B |
$0.03B |
1.19 |
2021-09-30 |
$0.03B |
$0.03B |
0.93 |
2021-06-30 |
$0.03B |
$0.03B |
0.84 |
2021-03-31 |
$0.03B |
$0.03B |
0.89 |
2020-12-31 |
$0.03B |
$0.01B |
3.09 |
2020-09-30 |
$0.03B |
$0.01B |
2.03 |
2020-06-30 |
$0.03B |
$0.00B |
20.20 |
2020-03-31 |
$0.03B |
$-0.00B |
-28.53 |
2019-12-31 |
$0.03B |
$0.00B |
6.34 |
2019-09-30 |
$0.03B |
$-0.00B |
-27.52 |
2019-06-30 |
$0.03B |
$0.00B |
7.53 |
2019-03-31 |
$0.03B |
$0.01B |
3.85 |
2018-12-31 |
$0.03B |
$0.01B |
2.47 |
2018-09-30 |
$0.02B |
$0.02B |
1.10 |
2018-06-30 |
$0.02B |
$0.02B |
0.75 |
2018-03-31 |
$0.02B |
$0.03B |
0.62 |
2017-12-31 |
$0.01B |
$0.03B |
0.47 |
2017-09-30 |
$0.02B |
$0.02B |
0.77 |
2017-06-30 |
$0.02B |
$0.03B |
0.67 |
2017-03-31 |
$0.02B |
$0.02B |
1.02 |
2016-12-31 |
$0.02B |
$0.02B |
0.90 |
2016-09-30 |
$0.02B |
$0.03B |
0.71 |
2016-06-30 |
$0.02B |
$0.02B |
0.90 |
2016-03-31 |
$0.02B |
$0.02B |
0.78 |
2015-12-31 |
$0.02B |
$0.03B |
0.70 |
2015-09-30 |
$0.02B |
$0.03B |
0.79 |
2015-06-30 |
$0.02B |
$0.03B |
0.65 |
2015-03-31 |
$0.02B |
$0.04B |
0.47 |
2014-12-31 |
$0.02B |
$0.04B |
0.41 |
2014-09-30 |
$0.02B |
$0.01B |
1.69 |
2014-06-30 |
$0.02B |
$0.00B |
8.09 |
2014-03-31 |
$0.02B |
$0.01B |
2.18 |
2013-12-31 |
$0.02B |
$0.01B |
2.66 |
2013-09-30 |
$0.02B |
$0.01B |
2.46 |
2013-06-30 |
$0.02B |
$0.01B |
2.98 |
2013-03-31 |
$0.02B |
$0.01B |
2.15 |
2012-12-31 |
$0.02B |
$0.01B |
1.71 |
2012-09-30 |
$0.02B |
$0.01B |
1.79 |
2012-06-30 |
$0.02B |
$0.01B |
1.66 |
2012-03-31 |
$0.02B |
$0.01B |
1.34 |
2011-12-31 |
$0.02B |
$0.01B |
1.37 |
2011-09-30 |
$0.02B |
$0.01B |
1.06 |
2011-06-30 |
$0.02B |
$0.02B |
1.01 |
2011-03-31 |
$0.02B |
$0.00B |
3.68 |
2010-12-31 |
$0.02B |
$-0.00B |
-6.96 |
2010-09-30 |
$0.02B |
$-0.00B |
-6.50 |
2010-06-30 |
$0.02B |
$-0.00B |
-16.56 |
2010-03-31 |
$0.02B |
$0.00B |
6.19 |
2009-12-31 |
$0.01B |
$0.01B |
1.80 |
2009-09-30 |
$0.01B |
$0.01B |
1.54 |
2009-06-30 |
$0.02B |
$0.01B |
1.90 |
2009-03-31 |
$0.02B |
$0.01B |
3.50 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical & Dental Supplies |
$0.002B |
$0.049B |
Biolaw Technology, Inc. is the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
|